Summary We have developed chimeric Fab fragments of MAb A7 (chA7Fab) and have reported on their potential usefulness as a carrier of neocarzinostatin (NCS). However, a large amount of chA7Fab accumulates in the kidneys which might cause renal failure. This was one of the major side-effects of the chA7Fab-NCS immunoconjugate administered to humans. To decrease the kidney accumulation of chA7Fab, chA7Fab was biotinylated and administered with a subsequent injection of avidin to nude mice with pancreatic cancer. The accumulation of biotinylated chA7Fab in the blood and the kidneys decreased significantly after the injection of avidin. In a separate experiment with biotinylated chA7Fab-NCS, the blood and kidney accumulation decreased significantly after the injection of avidin. These findings suggest that the injection of biotinylated chA7Fab complexed with NCS followed by avidin may be safer and may permit the administration of larger doses of NCS without the subsequent development of renal failure.
Introduction
Pancreatic cancer is one of the most lethal of all cancers. One of the reasons for its high mortality is the lack of effective chemotherapy. A number of murine monoclonal antibodies (MAbs) have been linked to various anti-tumour drugs, cytotoxins and enzymes in an attempt to increase the effectiveness of chemotherapy (Apelgren et al., 1990) . We have also produced MAb A7, which reacts with pancreatic and colonic carcinomas, from human colonic carcinomas, and covalently conjugated it with the anti-cancer drug, neocarzinostatin (NCS) (Fukuda, 1985) . A7-NCS has been used clinically for the treatment of patients with advanced colorectal and pancreatic cancers. However, human antimouse antibody (HAMA) was detected in all patients who received A7-NCS . HAMA usually increases the clearance of the administered MAb, thus reducing the MAb tumour accumulation and possibly resulting in lower therapeutic efficacy of the MAb-drug conjugate.
In Fujita's previous study, more than 70% of the NCS was inactivated by the serum within 120 min (Fujita et al., 1970) . In general, because the Fab fragments of MAbs are able to penetrate target tumours, they may be more suitable as carriers of anti-cancer agents such as NCS which are inactivated rapidly in the blood.
For these reasons, we have developed chimeric Fab fragments of MAb A7 (chA7Fab) as a carrier of NCS. In a previous study using nude mice bearing pancreatic carcinoma (which reacts with MAb A7), a larger amount of 1251-labelled chA7Fab accumulated in the pancreatic carcinoma compared with that of '25I-labelled MAb A7. Regarding normal tissue accumulation, however, more chA7Fab than 125I-labelled MAb A7 accumulated in the kidney because most of the intravenously injected chA7Fab was cleared via the kidney. Because renal dysfunction is one of the major side-effects of NCS chemotherapy in human, the kidney accumulation of chA7Fab should be minimised when it is administered as a carrier of NCS.
The association constant of the avidin-biotin binding is approximately 1015 M-1, and much greater than that of antigen-antibody interactions (Green, 1963) . Because avidin has four biotin-binding sites per molecule, aggregates formed by avidin and biotinylated antibody are produced if avidin is injected following the administration of biotinylated antibody. Once such aggregates are formed in the body, they could be taken up rapidly by the reticuloendothelial system and their accumulation in the blood and kidney should decrease accordingly. In this study we investigated the in vivo distribution of biotinylated chA7Fab and biotinylated chA7Fab-NCS after the administration of avidin which appeared to decrease the accumulation of chA7Fab in the kidney. Hours after antibody injection I h 6h 12h 24h
Materials and methods
Hours after antibody injection Figure 1 The accumulation of 125I-labelled biotinylated chA7Fab in the blood, HPC-YS tumours and the normal tissues of mice with or without the subsequent administration of avidin (a, blood; b, tumour; c, heart; d, liver; e, spleen; f, pancreas; g, colon; h, kidney). The mice received an injection of avidin in 100p1 of 50mM HEPES in 5% mannitol buffer or the same solution without avidin, respectively, at 1, 6, 12 and 24 h after the injection of 125I-labelled biotinylated chA7Fab. The pattern of tumour accumulation of 125I-labelled biotinylated chA7Fab with the subsequent administration of avidin was similar to that without administration of avidin. The blood concentration of '25I-labelled biotinylated chA7Fab was significantly lower following the administration of avidin than without its administration at 1 and 6h after the injection of 125I-labelled biotinylated chA7Fab. The kidney accumulation of 1251-labelled biotinylated chA7Fab was significantly lower with the subsequent administration of avidin than it was without the administration of avidin at I and 6h after antibody injection. The accumulation of 125I-labelled biotinylated Neocarzinostatin conjugation to chA7Fab ChA7Fab was conjugated to NCS (Kayaku, Tokyo, Japan) with N-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP) as described previously by Yamaguchi et al. (1993) . The conjugation ratio was 1 mol of NCS per mol of chA7Fab.
Preparation of radiolabelled chA7Fab and chA7Fab-NCS Radiolabelling of chA7Fab with 1251 (Amersham Japan Ltd., IMS 30, Japan) was performed by the chloramine-T method (Hunter and Greenwood, 1962 The tumour accumulation of "2s1-labelled biotinylated chA7Fab with and without the administration of avidin decreased linearly with time. In contrast, the concentration of 1251-labelled biotinylated chA7Fab in the blood was lower with the administration of avidin than without it. Significant differences were observed between the two groups at 1 and 6 h after injection (P<0.05). As for normal tissues, the kidney accumulation of 125I-labelled biotinylated chA7Fab
was lower with the administration of avidin than that without it. Significant differences were observed between the two groups at 1 and 6 h after injection (P<0.05). The accumulation of "251-labelled biotinylated chA7Fab in the spleen and the liver was higher with the administration of avidin than that without it. Significant differences were observed between the two groups at 1 and 6 h after injection for the spleen and the liver (P<0.05) (Figure 1 ).
Biodistribution of '25"-labelled chA7Fab-NCS after administration of avidin in nude mice bearing tumours The tumour accumulation of '25I-labelled biotinylated chA7Fab-NCS with the administration of avidin was almost identical with that without administration of avidin.
In contrast, the concentration of "25I-labelled biotinylated ch7Fab-NCS in the blood was lower with the administration of avidin than without it. Significant differences were observed between the two groups at 1, 6 and 12 h after injection (P<0.05). The kidney accumulation of '251-labelled biotinylated chA7Fab-NCS was lower with the administration of avidin than that without it. Significant differences were observed between the two groups at 1 and 6 h after injection (P< 0.05). The accumulation of '251-labelled biotinylated chA7Fab-NCS in the spleen and the liver was higher with the administration of avidin than that without it. Significant differences were observed between the two groups at 1 and 6 h after injection for the spleen and at 1 h for the liver (P<0.05) (Figure 2 ).
Discussion
We have reported that MAb A7 can be linked covalently to NCS and that this conjugate can be used to treat patients with colorectal cancer. Although some of the patients who 59 599 chA7Fab in the spleen and the liver was higher following the administration of avidin than it was without the administration of avidin. Significant differences were observed between the two groups at 1 and 6 h after the antibody injection for the spleen and the liver. A, with the subsequent administration of avidin; B, no avidin administration; point, mean; bar, s.d.; *, significant difference (P<O.05). have been treated with A7 -NCS have had a partial regression of their tumours, HAMA was produced in all patients who received A7-NCS . HAMA production should decrease when NCS conjugated to a human/mouse chimeric MAb is administered to humans, because the origin of the Fc portion of the chimeric MAb, which is the most immunopotent region of intact MAbs (Spiegelberg et al., 1965) , is human. Fujita et al. (1970) reported that more than 70% of the anti-tumour activity of NCS was inactivated by 10% mouse serum within 120 min in an in vitro experiment. In general, the small variable fragment of the MAb molecule has the ability to leave the vascular space rapidly and to penetrate easily into target tumour tissue. Thus, Fab fragments of MAb A7 may be suitable as carriers of anti-cancer agents like NCS which are inactivated rapidly in the blood. For these reasons, we have prepared chA7Fab and have conjugated it to NCS. ChA7Fab specifically accumulated in the tumour (Otsuji et al., 1995) and the conjugate showed greater anti-tumour activity against human pancreatic cancer growth in nude mice than did A7 -NCS and completely suppressed tumour growth (Otsuji et al., 1996) . However, a large amount of chA7Fab accumulated in the kidney, consistent with the results of Hansson et al. (1988) who have demonstrated the rapid clearance of non-Fc-bearing antibody fragments. This clearance is thought to occur mainly via the kidney. Because renal dysfunction is one of the most lethal adverse effects of NCS in humans, it would seem prudent to reduce the kidney accumulation of chA7Fab, conjugated to NCS. Avidin, a 66 kDa protein found in egg whites, has a strong avidity for biotin, a 244 Da vitamin found in low concentrations in tissues and in blood (Mock and Dubois, 1986) . The association constant of the avidin-biotin bond is 10' M-' (Green, 1963) and, as such, is 106-fold greater than most antigen-antibody interactions. The bond formation is completed within 15 min and, once formed, the bond is extremely stable. The in vitro method of biotinylation of proteins has been well described, and any type of immunoglobulin can be biotinylated easily.
The strong affinity of the avidin-biotin system has drawn the attention of several researchers working on background reduction in the imaging applications of MAbs (Hnatowich et al., 1987; Sinitsyn et al., 1989; Ogihara et al., 1994) . This is thought to be secondary to the trapping by the reticuloendothelial system of avidin -biotinylated MAb aggregates formed in the serum. These results suggested that avidin might be useful in targeting NCS conjugated to chA7Fab away from the kidneys. As shown in Figure 2a , a significantly smaller amount of biotinylated chA7Fab-NCS is retained in the blood in the groun of mice iniected with avidin comnared with those not injected with avidin. In a previous study, '25f. labelled chA7Fab-NCS was cleared from the blood via the kidney and a large amount of chA7Fab-NCS accumulated in the kidney (Otsuji et al., 1994) . As shown in Figure 2h , the kidney concentration of biotinylated chA7Fab-NCS decreased approximately 50% by the subsequent administration of avidin. Decreased renal dysfunction can be expected by the administration of biotinylated chA7Fab-NCS along with avidin. As for the tumours, the accumulation of biotinylated chA7Fab -NCS was not affected by the administration of avidin, while it did significantly increase the accumulation of biotinylated chA7Fab -NCS in the spleen and the liver. However, the splenic accumulation of biotinylated chA7Fab conjugated to NCS is unlikely to be toxic to patients because there have been no reports of adverse effects of NCS on splenic function. Although a relatively large amount of biotinylated chA7Fab-NCS also accumulated in the liver, NCS is reported to be inactivated rapidly in the liver (Fujita et al., 1970) , which may minimise its toxicity. In another experiment, the distribution of biotinylated chA7Fab with a subsequent injection of avidin was similar to that of biotinylated chA7Fab-NCS. In the separate experiments using unbiotinylated chA7Fab with a subsequent injection of avidin, the distribution of unbiotinylated chA7Fab was identical to that without injection of avidin (data not shown). Therefore, this high accumulation of biotinylated chA7Fab-NCS in the spleen and the liver was considered due to the trapping of the avidin-biotinylated chA7Fab aggregates by the reticuloendothelial system.
Because avidin-biotinylated MAb aggregates were formed in the serum, the immunogenity of this complex might be enhanced. However, with the avidin doses used in this study, we did not observe any side-effects in the animals. Other researchers have also reported that such doses of avidin are not toxic (Hnatowich et al., 1987; Ogihara et al., 1994; Paganelli et al., 1990) .
From these results, we conclude that the accumulation of biotinylated chA7Fab-NCS in the blood and the kidneys can be decreased by the subsequent administration of avidin and this modification does not reduce tumour accumulation. Thus, biotinylated chA7Fab may be a suitable carrier of NCS and result in less kidney toxicity if avidin is also administered, preferably between 1 and 6 h after the administration of antibody conjugate.
